AlphAIAlphAI — Financial news for AI agents
investing.comAUG 262 min read$ARGX

Argenx upgraded to Buy at UBS on Vyvgart’s $20 bln sales potential

UBS upgraded Argenx (ARGX) to Buy with a $1,400 price target, citing Vyvgart's potential for $18B peak sales and a strong pipeline. The stock rose 2.8% in Brussels. Analyst Xian Deng highlighted better-than-expected Phase 3 data and underappreciated pipeline assets, including empasiprubart and a recent $2B acquisition.

Original reporting
investing.com
Published Aug 26, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$ARGX
Bullish
high confidence
Mentioned
$ARGX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ARGXBullishHigh
01

Why it matters

The upgrade and higher target price reflect UBS’s confidence in upcoming trial readouts and a $2 bn acquisition that diversifies the pipeline.

02

Market read

Analyst upgrade with a sizable price target increase can trigger short‑term buying pressure and influence peer valuations.

03

What to watch

Potential competition in myositis and Sjögren’s disease could limit market share.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Argenx (ARGX) is a European biotech focused on rare‑disease antibodies. The firm’s flagship product Vyvgart targets CIDP and is expanding into myositis and Sjögren’s disease.

Company-level read

Ticker impact

$ARGXBullishHigh confidence
Context

UBS upgraded Argenx to Buy with a new $1,400 price target, citing $20 bn peak sales potential for Vyvgart and stronger Phase 3 data.

Expected impact

Potential further price appreciation if sales outlook holds.

Evidence & confidence

Upgrade reflects fresh clinical data and a larger sales forecast, which can attract buying pressure.

Market effects

Sector

Positive signal for biotech sector and rare‑disease therapeutics.

Regional

European biotech stocks may see modest gains.

Global

Highlights growing demand for immunology drugs worldwide.

Counterpoint

What could challenge this read

Upgrade may be premature; Phase 3 data still carries binary risk and sales forecasts could be optimistic.

Key entities

  • Company
    Argenx

    Biotech developer of Vyvgart.

  • Analyst
    UBS

    Issued the upgrade and new price target.

Read at source← All news

Also covered by

2 outlets

Related articles

OCT 23
$ARGXHighAI 8/10

argenx (ARGX) Q3 2026 Earnings Call Transcript

argenx (ARGX) reported Q3 2026 revenue of $1.7B, up 54% YoY. The company anticipates 5 potential drug launches in 2027, including VYVGART for new indications and empasiprubart for MMN. argenx also plans increased R&D and SG&A expenses for 2026, totaling $4B, driven by pipeline advancements and the Forte acquisition.

finance.yahoo.com3 min
OCT 22
Med

argenx SE (ARGNF) (Q3 2026) Earnings Call Highlights: VYVGART Sales Surge 54%

argenx SE (ARGNF) reported a 54% surge in VYVGART sales. The company increased 2026 OpEx guidance to $4B, with half attributed to the Forte acquisition. Management expects growth in MG and CIDP revenues, with additional indications driving Vision 2030. Potential 2027 launches include MMN, pending positive IMPASSION data. The FDA requested an additional dermatomyositis trial, and management remains confident in delivering Vision 2030.

finance.yahoo.com3 min
OCT 22
$ARGXHighAI 8/10

argenx SE (ARGNF) (Q3 2026) Earnings Call Highlights: VYVGART Sa

argenx SE reported Q3 2026 product net sales of $1.7B, up 54% YoY. VYVGART's seronegative MG launch saw strong access. Phase 3 ALKIVIA results support autoimmune myositis expansion. Operating expenses are rising to $4B, up 45% YoY, due to acquisitions and pipeline investments. The FDA required an additional trial for dermatomyositis, delaying approval. Empasiprubart's Phase 3 study in MMN is expected in December. The company did not provide formal revenue guidance, citing uncertainty.

gurufocus.com2 min
OCT 22
$ARGXMedAI 8/10

Jefferies reiterates argenx stock Buy rating after Q3 beat

Jefferies reiterated a Buy rating and $1,200 price target for argenx SE (ARGX) after its Q3 results. The company reported Vyvgart revenues of $1.7B, a 5% beat, and EPS of $7.80, in line with estimates. Operating expenses were higher due to the Forte deal. Analysts expect data readouts and revenue growth to drive future performance, with projections of $6.5B in FY2026 revenues. Other analysts have mixed price target adjustments.

investing.com2 min